Menopausal symptoms in breast cancer survivors nearly 6 years after diagnosis

Research output: Contribution to journalArticleResearchpeer-review

Abstract

OBJECTIVE: We investigated the prevalence and severity of menopausal symptoms, nearly 6 years from diagnosis, in women who had not experienced recurrent breast cancer or a new primary breast cancer (active disease) and were no longer taking oral adjuvant endocrine therapy (OAET). METHODS: A total of 1,683 women recruited within 12 months of diagnosis with invasive breast cancer completed an enrollment questionnaire and five annual follow-up questionnaires. Only women who had never reported active disease and were not taking OAET at their fifth follow-up were included in the analysis. Women previously recruited to a study of sex steroid levels provided community control data. Menopausal symptoms were assessed with the Menopause-Specific Quality of Life Questionnaire (MenQOL). RESULTS: Eight hundred forty-three women without active disease and not taking OAET completed the fifth follow-up questionnaire, on average, 5.8 years after diagnosis. Most had stage I (59.5 ) and hormone receptor-positive disease (77.9 ) at diagnosis and were postmenopausal (92.8 ). Those aged 50 to 59 years were more likely to report any symptoms (P = 0.01) and more severe symptoms (P <0.001) than older and younger women. There was no independent impact of chemotherapy on MenQOL vasomotor and sexual domain scores. Women with breast cancer had significantly higher vasomotor domain (P = 0.002) and sexual domain (P = 0.004) scores than community controls. CONCLUSIONS: Vasomotor and sexual symptoms are highly prevalent in breast cancer survivors and are not simply a function of OAET or chemotherapy. Given the adverse impact of these symptoms, effective interventions are needed to alleviate them in women who have completed their breast cancer treatment.
Original languageEnglish
Pages (from-to)1075 - 1081
Number of pages7
JournalMenopause
Volume21
Issue number10
DOIs
Publication statusPublished - 2014

Cite this

@article{540a83345c1043c79cacfa85944ac89c,
title = "Menopausal symptoms in breast cancer survivors nearly 6 years after diagnosis",
abstract = "OBJECTIVE: We investigated the prevalence and severity of menopausal symptoms, nearly 6 years from diagnosis, in women who had not experienced recurrent breast cancer or a new primary breast cancer (active disease) and were no longer taking oral adjuvant endocrine therapy (OAET). METHODS: A total of 1,683 women recruited within 12 months of diagnosis with invasive breast cancer completed an enrollment questionnaire and five annual follow-up questionnaires. Only women who had never reported active disease and were not taking OAET at their fifth follow-up were included in the analysis. Women previously recruited to a study of sex steroid levels provided community control data. Menopausal symptoms were assessed with the Menopause-Specific Quality of Life Questionnaire (MenQOL). RESULTS: Eight hundred forty-three women without active disease and not taking OAET completed the fifth follow-up questionnaire, on average, 5.8 years after diagnosis. Most had stage I (59.5 ) and hormone receptor-positive disease (77.9 ) at diagnosis and were postmenopausal (92.8 ). Those aged 50 to 59 years were more likely to report any symptoms (P = 0.01) and more severe symptoms (P <0.001) than older and younger women. There was no independent impact of chemotherapy on MenQOL vasomotor and sexual domain scores. Women with breast cancer had significantly higher vasomotor domain (P = 0.002) and sexual domain (P = 0.004) scores than community controls. CONCLUSIONS: Vasomotor and sexual symptoms are highly prevalent in breast cancer survivors and are not simply a function of OAET or chemotherapy. Given the adverse impact of these symptoms, effective interventions are needed to alleviate them in women who have completed their breast cancer treatment.",
author = "Davis, {Susan Ruth} and Mary Panjari and Robinson, {Penelope Jane} and Pamela Fradkin and Bell, {Robin Jean}",
year = "2014",
doi = "10.1097/gme.0000000000000219",
language = "English",
volume = "21",
pages = "1075 -- 1081",
journal = "Menopause",
issn = "1072-3714",
publisher = "Lippincott Williams & Wilkins",
number = "10",

}

Menopausal symptoms in breast cancer survivors nearly 6 years after diagnosis. / Davis, Susan Ruth; Panjari, Mary; Robinson, Penelope Jane; Fradkin, Pamela; Bell, Robin Jean.

In: Menopause, Vol. 21, No. 10, 2014, p. 1075 - 1081.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Menopausal symptoms in breast cancer survivors nearly 6 years after diagnosis

AU - Davis, Susan Ruth

AU - Panjari, Mary

AU - Robinson, Penelope Jane

AU - Fradkin, Pamela

AU - Bell, Robin Jean

PY - 2014

Y1 - 2014

N2 - OBJECTIVE: We investigated the prevalence and severity of menopausal symptoms, nearly 6 years from diagnosis, in women who had not experienced recurrent breast cancer or a new primary breast cancer (active disease) and were no longer taking oral adjuvant endocrine therapy (OAET). METHODS: A total of 1,683 women recruited within 12 months of diagnosis with invasive breast cancer completed an enrollment questionnaire and five annual follow-up questionnaires. Only women who had never reported active disease and were not taking OAET at their fifth follow-up were included in the analysis. Women previously recruited to a study of sex steroid levels provided community control data. Menopausal symptoms were assessed with the Menopause-Specific Quality of Life Questionnaire (MenQOL). RESULTS: Eight hundred forty-three women without active disease and not taking OAET completed the fifth follow-up questionnaire, on average, 5.8 years after diagnosis. Most had stage I (59.5 ) and hormone receptor-positive disease (77.9 ) at diagnosis and were postmenopausal (92.8 ). Those aged 50 to 59 years were more likely to report any symptoms (P = 0.01) and more severe symptoms (P <0.001) than older and younger women. There was no independent impact of chemotherapy on MenQOL vasomotor and sexual domain scores. Women with breast cancer had significantly higher vasomotor domain (P = 0.002) and sexual domain (P = 0.004) scores than community controls. CONCLUSIONS: Vasomotor and sexual symptoms are highly prevalent in breast cancer survivors and are not simply a function of OAET or chemotherapy. Given the adverse impact of these symptoms, effective interventions are needed to alleviate them in women who have completed their breast cancer treatment.

AB - OBJECTIVE: We investigated the prevalence and severity of menopausal symptoms, nearly 6 years from diagnosis, in women who had not experienced recurrent breast cancer or a new primary breast cancer (active disease) and were no longer taking oral adjuvant endocrine therapy (OAET). METHODS: A total of 1,683 women recruited within 12 months of diagnosis with invasive breast cancer completed an enrollment questionnaire and five annual follow-up questionnaires. Only women who had never reported active disease and were not taking OAET at their fifth follow-up were included in the analysis. Women previously recruited to a study of sex steroid levels provided community control data. Menopausal symptoms were assessed with the Menopause-Specific Quality of Life Questionnaire (MenQOL). RESULTS: Eight hundred forty-three women without active disease and not taking OAET completed the fifth follow-up questionnaire, on average, 5.8 years after diagnosis. Most had stage I (59.5 ) and hormone receptor-positive disease (77.9 ) at diagnosis and were postmenopausal (92.8 ). Those aged 50 to 59 years were more likely to report any symptoms (P = 0.01) and more severe symptoms (P <0.001) than older and younger women. There was no independent impact of chemotherapy on MenQOL vasomotor and sexual domain scores. Women with breast cancer had significantly higher vasomotor domain (P = 0.002) and sexual domain (P = 0.004) scores than community controls. CONCLUSIONS: Vasomotor and sexual symptoms are highly prevalent in breast cancer survivors and are not simply a function of OAET or chemotherapy. Given the adverse impact of these symptoms, effective interventions are needed to alleviate them in women who have completed their breast cancer treatment.

UR - http://journals.lww.com/menopausejournal/pages/articleviewer.aspx?year=2014&issue=10000&article=00008&type=abstract

U2 - 10.1097/gme.0000000000000219

DO - 10.1097/gme.0000000000000219

M3 - Article

VL - 21

SP - 1075

EP - 1081

JO - Menopause

JF - Menopause

SN - 1072-3714

IS - 10

ER -